Article
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
The Lancet. Oncology - 1 Apr 2022
Kristeleit Rebecca, Lisyanskaya Alla, Fedenko Alexander, Dvorkin Mikhail, de Melo Andreia Cristina, Shparyk Yaroslav, Rakhmatullina Irina, Bondarenko Igor, Colombo Nicoletta, Svintsitskiy Valentyn, Biela Luciano, Nechaeva Marina, Lorusso Domenica, Scambia Giovanni, Cibula David, Póka Róbert, Oaknin Ana, Safra Tamar, Mackowiak-Matejczyk Beata, Ma Ling, Thomas Daleen, Lin Kevin K, McLachlan Karen, Goble Sandra, Oza Amit M
Abstract excerpt
BACKGROUND: Few prospective studies have compared poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors to chemotherapy for the treatment of BRCA1-mutated or BRCA2-mutated ovarian carcinoma. We aimed to assess rucaparib versus platinum-based and non-platinum-based chemotherapy in this setting. METHODS: In this open-label, randomised, controlled, phase 3 study (ARIEL4), conducted in 64 hospitals and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.